专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

101. 发明专利

SG11201401479SA APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES 未知
公开(公告)号：SG11201401479SA
公开(公告)日：2014-07-30
申请号：SG11201401479S
申请日：2012-10-11
申请人： ABBVIE INC
发明人： WANG LE , DOHERTY GEORGE , WANG XILU , TAO ZHI-FU , BRUNKO MILAN , KUNZER AARON R , WENDT MICHAEL D , SONG XIAOHONG , FREY ROBIN , HANSEN TODD M , SULLIVAN GERARD M , JUDD ANDREW , SOUERS ANDREW
IPC分类号： C07D417/14
摘要： Disclosed are compounds (I) which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and compounds (I) for use in the methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.

102. 发明专利

DOP2014000074A AGENTES INDUCTORES DE LA APOPTOSIS QUE PUEDEN USARSE PARA TRATAR EL CÁNCER Y LAS ENFERMEDADES INMUNES Y AUTOINMUNES 未知
公开(公告)号：DOP2014000074A
公开(公告)日：2014-07-15
申请号：DO2014000074
申请日：2014-04-11
申请人： ABBVIE INC
发明人： WANG XILU , WANG LE , KUNZER AARON R , WENDT MICHAEL D , SULLIVAN GERARD M , DOHERTY GEORGE , HANSEN TODD M , SOUERS ANDREW , TAO ZHI-FU , BRUNKO MILAN , SONG XIAOHONG , FREY ROBIN , JUDD ANDREW
IPC分类号： C07D417/14
摘要： Compuestos que inhiben la actividad de las proteínas antiapoptóticas Bcl-xL, composiciones que contienen dichos compuestos y métodos para tratar enfermedades en las que se expresan las proteínas antiapoptóticas Bcl-xL.

103. 发明专利

NZ599778A Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases 未知
公开(公告)号：NZ599778A
公开(公告)日：2014-04-30
申请号：NZ59977810
申请日：2010-06-01
申请人： ABBVIE INC
发明人： BRUNCKO MILAN , DING HONG , DOHERTY GEORGE A , ELMORE STEVEN W , HASVOLD LISA , HEXAMER LAURA , KUNZER AARON , MANTEI ROBERT A , MCCLELLAN WILLIAM J , PARK CHANG H , PARK CHEOL-MIN , PETROS ANDREW M , SONG XIAOHONG , SOUERS ANDREW J , SULLIVAN GERARD M , TAO ZHI-FU , WANG GARY T , WANG LE , WANG XILU , WENDT MICHAEL D , HANSEN TODD M
IPC分类号： C07D405/12 , A61K31/404 , A61K31/416 , A61K31/4184 , A61K31/4192 , A61K31/496 , A61P35/00 , C07D209/32 , C07D211/96 , C07D213/64 , C07D215/20 , C07D217/16 , C07D231/56 , C07D235/08 , C07D235/26 , C07D249/04 , C07D249/18 , C07D295/125 , C07D295/14 , C07D295/155 , C07D309/14 , C07D401/12 , C07D405/14
摘要： 599778 Disclosed are 2-(1H-indazol-4-yloxy) / 2-(1H-benzimidazol-4-yloxy) and 2-(1H-benzotriazol-4-yloxy) N-({ pyridin-3-yl/phenyl} sulfonyl)benzamide derivatives, wherein the claimed compounds are selected from N-({ 5-chloro-6-[(4,4-difluorocyclohexyl)methoxy]pyridin-3-yl} sulfonyl)-4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl} piperazin-1-yl)-2-(1H-indazol-4-yloxy)benzamide; N-({ 6-[(trans-4-carbamoylcyclohexyl)methoxy]-5-chloropyridin-3-yl} sulfonyl)-4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl} piperazin-1-yl)-2-(1H-indazol-4-yloxy)benzamide; 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl} piperazin-1-yl)-N-[(4-{ [(trans-4-cyanocyclohexyl)methyl]amino} -3-nitrophenyl)sulfonyl]-2-(1H-indazol-4-yloxy)benzamide; N-({ 5-chloro-6-[2-(1H-imidazol-1-yl)ethoxy]pyridin-3-yl} sulfonyl)-4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl} piperazin-1-yl)-2-(1H-indazol-4-yloxy)benzamide; N-({ 5-chloro-6-[(1-methyl-1H-imidazol-5-yl)methoxy]pyridin-3-yl} sulfonyl)-4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl} piperazin-1-yl)-2-(1H-indazol-4-yloxy)benzamide; 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl} piperazin-1-yl)-N-{ [5-fluoro-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl} -2-(1H-indazol-4-yloxy)benzamide; N-{ [5-chloro-6-(1,4-dioxan-2-ylmethoxy)pyridin-3-yl]sulfonyl} -4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl} piperazin-1-yl)-2-(1H-indazol-4-yloxy)benzamide; N-({ 5-chloro-6-[(4,4-difluoro-1-hydroxycyclohexyl)methoxy]pyridin-3-yl} sulfonyl)-4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl} piperazin-1-yl)-2-(1H-indazol-4-yloxy)benzamide; N-({ 5-chloro-6-[(2,2-difluorocyclopropyl)methoxy]pyridin-3-yl} sulfonyl)-4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl} piperazin-1-yl)-2-(1H-indazol-4-yloxy)benzamide; N-({ 5-chloro-6-[(trans-4-cyanocyclohexyl)methoxy]pyridin-3-yl} sulfonyl)-4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl} piperazin-1-yl)-2-(1H-indazol-4-yloxy)benzamide; N-({ 5-chloro-6-[(cis-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl} sulfonyl)-4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl} piperazin-1-yl)-2-(1H-indazol-4-yloxy)benzamide; N-({ 5-chloro-6-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl} sulfonyl)-4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl} piperazin-1-yl)-2-(1H-indazol-4-yloxy)benzamide; N-({ 3-chloro-4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]phenyl} sulfonyl)-4-(4-{ [4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl} piperazin-1-yl)-2-(1Hindazol-4-yloxy)benzamide; 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl} piperazin-1-yl)-N-({ 4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3-(trifluoromethyl)phenyl} sulfonyl)-2-(1Hindazol-4-yloxy)benzamide; 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl} piperazin-1-yl)-N-{ [3-chloro-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]sulfonyl} -2-(1H-indazol-4-yloxy)benzamide; 2-(1H-benzimidazol-4-yloxy)-N-({ 3-chloro-4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]phenyl} sulfonyl)-4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl} piperazin-1-yl)benzamide; 2-(1H-benzimidazol-4-yloxy)-4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl} piperazin-1-yl)-N-{ [5-chloro-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl} benzamide; 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl} piperazin-1-yl)-N-({ 3-cyano-4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]phenyl} sulfonyl)-2-(1H-indazol-4-yloxy)benzamide; N-{ [3-chloro-4-(1,4-dioxan-2-ylmethoxy)phenyl]sulfonyl} -4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl} piperazin-1-yl)-2-(1H-indazol-4-yloxy)benzamide; 2-(1H-benzimidazol-4-yloxy)-N-[(5-chloro-6-{ [(2S)-4-cyclopropylmorpholin-2-yl]methoxy} pyridin-3-yl)sulfonyl]-4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl} piperazin-1-yl)benzamide; N-[(5-chloro-6-{ [(2S)-4-cyclopropylmorpholin-2-yl]methoxy} pyridin-3-yl)sulfonyl]-4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl} piperazin-1-yl)-2-(1H-indazol-4-yloxy)benzamide; methyl 2-{ [(4-{ [4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl} piperazin-1-yl)-2-(1H-indazol-4-yloxy)benzoyl]sulfamoyl} -2-nitrophenyl)amino]methyl} morpholine-4-carboxylate; 2-{ [(4-{ [4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl} piperazin-1-yl)-2-(1H-indazol-4-yloxy)benzoyl]sulfamoyl} -2-nitrophenyl)amino]methyl} -N-ethyl-Nmethylmorpholine-4-carboxamide; 2-{ [(4-{ [2-(1H-benzimidazol-4-yloxy)-4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl} piperazin-1-yl)benzoyl]sulfamoyl} -2-nitrophenyl)amino]methyl} -N-ethyl-N-methylmorpholine-4-carboxamide; N-({ 5-chloro-6-[(trans-4-ethyl-4-hydroxycyclohexyl)methoxy]pyridin-3-yl} sulfonyl)-4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl} piperazin-1-yl)-2-(1H-indazol-4-yloxy)benzamide; N-({ 5-chloro-6-[(cis-4-ethyl-4-hydroxycyclohexyl)methoxy]pyridin-3-yl} sulfonyl)-4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl} piperazin-1-yl)-2-(1H-indazol-4-yloxy)benzamide; 5-chloro-N-({ 5-chloro-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl} sulfonyl)-4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl} piperazin-1-yl)-2-(1Hindazol-4-yloxy)benzamide; 5-chloro-4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl} piperazin-1-yl)-N-[(4-{ [(4-fluorotetrahydro-2H-pyran-4-yl)methyl]amino} -3-nitrophenyl)sulfonyl]-2-(1Hindazol-4-yloxy)benzamide; N-({ 5-chloro-6-[(cis-1-fluoro-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl} sulfonyl)-4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl} piperazin-1-yl)-2-(1Hindazol-4-yloxy)benzamide; N-({ 5-chloro-6-[(trans-1-fluoro-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl} sulfonyl)-4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl} piperazin-1-yl)-2-(1H-indazol-4-yloxy)benzamide; 2-(1H-benzotriazol-4-yloxy)-4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl} piperazin-1-yl)-N-[(4-{ [(4-fluorotetrahydro-2H-pyran-4-yl)methyl]amino} -3-nitrophenyl)sulfonyl]benzamide; 2-(1H-benzotriazol-4-yloxy)-N-({ 5-chloro-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl} sulfonyl)-4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl} piperazin-1-yl)benzamide; 2-(1H-benzimidazol-4-yloxy)-4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl} piperazin-1-yl)-N-{ [3-chloro-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]sulfonyl} benzamide; N-[(3-chloro-4-{ [4-fluoro-1-(oxetan-3-yl)piperidin-4-yl]methoxy} phenyl)sulfonyl]-4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl} piperazin-1-yl)-2-(1H-indazol-4-yloxy)benzamide; N-({ 5-chloro-6-[(cis-1-fluoro-4-hydroxycyclohexyl)methoxy]pyridin-3-yl} sulfonyl)-4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl} piperazin-1-yl)-2-(1H-indazol-4-yloxy)benzamide; 2-(1H-benzotriazol-4-yloxy)-4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl} piperazin-1-yl)-N-({ 4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3-nitrophenyl} sulfonyl)benzamide; N-[(5-chloro-6-{ [(1R,2R,4R,5R)-5-hydroxy-5-methylbicyclo[2.2.1]hept-2-yl]methoxy} pyridin-3-yl)sulfonyl]-4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl} piperazin-1-yl)-2-(1H-indazol-4-yloxy)benzamide; N-({ 5-chloro-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl} sulfonyl)-4-(4-{ [2-(4-chlorophenyl)-5,5-difluorocyclohex-1-en-1-yl]methyl} piperazin-1-yl)-2-(1H-indazol-4-yloxy)benzamide; N-[(5-chloro-6-{ [4-fluoro-1-(oxetan-3-yl)piperidin-4-yl]methoxy} pyridin-3-yl)sulfonyl]-4-(4-{ [2-(4-chlorophenyl)-5,5-difluorocyclohex-1-en-1-yl]methyl} piperazin-1-yl)-2-(1H-indazol-4-yloxy)benzamide; 2-(1H-benzotriazol-4-yloxy)-4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl} piperazin-1-yl)-N-({ 3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)benzamide; 4-(4-{ [2-(4-chlorophenyl)-5,5-difluorocyclohex-1-en-1-yl]methyl} piperazin-1-yl)-2-(1Hindazol-4-yloxy)-N-({ 3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)benzamide; 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl} piperazin-1-yl)-N-[(4-{ [(trans-4-hydroxy-4-methylcyclohexyl)methyl]amino} -3-nitrophenyl)sulfonyl]-2-(1Hindazol-4-yloxy)benzamide; 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl} piperazin-1-yl)-N-[(4-{ [(cis-4-hydroxy-4-methylcyclohexyl)methyl]amino} -3-nitrophenyl)sulfonyl]-2-(1H-indazol-4-yloxy)benzamide; 2-(1H-benzotriazol-4-yloxy)-4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl} piperazin-1-yl)-N-{ [4-({ [(2S)-4-cyclopropylmorpholin-2-yl]methyl} amino)-3-nitrophenyl]sulfonyl} benzamide; N-[(5-chloro-6-{ [4-fluoro-1-(oxetan-3-yl)piperidin-4-yl]methoxy} pyridin-3-yl)sulfonyl]-4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl} piperazin-1-yl)-2-(1H-indazol-4-yloxy)benzamide; 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl} piperazin-1-yl)-N-{ [4-({ [(2S)-4-cyclopropylmorpholin-2-yl]methyl} amino)-3-nitrophenyl]sulfonyl} -2-(1Hindazol-4-yloxy)benzamide; 2-(1H-benzimidazol-4-yloxy)-4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl} piperazin-1-yl)-N-{ [4-({ [(2S)-4-cyclopropylmorpholin-2-yl]methyl} amino)-3-nitrophenyl]sulfonyl} benzamide; N-({ 5-chloro-6-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl} sulfonyl)-4-(4-{ [2-(4-chlorophenyl)-5,5-difluorocyclohex-1-en-1-yl]methyl} piperazin-1-yl)-2-(1H-indazol-4-yloxy)benzamide; 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl} piperazin-1-yl)-N-({ 4-[(cis-4-hydroxy-4-methylcyclohexyl)methoxy]-3-nitrophenyl} sulfonyl)-2-(1H-indazol-4-yloxy)benzamide; 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl} piperazin-1-yl)-N-({ 4-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]-3-nitrophenyl} s

104. 发明专利

CA2859619A1 BROMODOMAIN INHIBITORS 未知
公开(公告)号：CA2859619A1
公开(公告)日：2013-07-04
申请号：CA2859619
申请日：2012-12-11
申请人： ABBVIE INC
发明人： WANG LE , PRATT JOHN K , MCDANIEL KEITH F , DAI YUJIA , FIDANZE STEVEN D , HASVOLD LISA , HOLMS JAMES H , KATI WARREN M , LIU DACHUN , MANTEI ROBERT A , MCCLELLAN WILLIAM J , SHEPPARD GEORGE S , WADA CAROL K
IPC分类号： C07D471/04 , A61K31/407 , A61P3/10 , A61P13/12 , A61P31/18 , A61P35/00
摘要： The present invention provides for compounds of formula (I) wherein A1, A2, A3, A4, X1, X2, Y1, L1, G1, Rx, and Ry have any of the values defined thereof in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).

105. 发明专利

CO6640274A2 Agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes 未知
公开(公告)号：CO6640274A2
公开(公告)日：2013-03-22
申请号：CO12226068
申请日：2012-12-13
申请人： ABBVIE INC
发明人： BRUNCKO MILAN , DING HONG , DOHERTY GEORGE , ELMORE STEVEN W , HASVOLD LISA A , HEXAMER LAURA , KUNZER AARON R , SONG XIAOHONG , SOUERS ANDREW J , SULLIVAN GERARD M , TAO ZHI-FU , WANG GARY T , WANG LE , WANG XILU , WENDT MICHAEL D , MANTEI ROBERT A , HANSEN TODD M
IPC分类号： C07D471/04 , A61K31/437 , A61K35/00
摘要： Compuestos que inhiben la actividad de las proteínas anti-apoptóticas Bcl-2, composiciones que contienen dichos compuestos y métodos para tratar enfermedades durante las cuales se expresa la proteína anti-apoptótica Bcl-2.

106. 发明专利

CR20120631A AGENTES INDUCTORES DE APOPTOSIS PARA EL TRATAMIENTO DEL CÀNCER Y DE ENFERMEDADES INMUNES Y AUTOINMUNES 未知
公开(公告)号：CR20120631A
公开(公告)日：2013-03-19
申请号：CR20120631
申请日：2012-12-12
申请人： ABBVIE INC
发明人： BRUNCKO MILAN , DING HONG , DOHERTY GEORGE , ELMORE STEVEN , HASVOLD LISA , HEXAMER LAURA , KUNZER AARON R , SONG XIAOHONG , SOUERS ANDREW J , SULLIVAN GERARD , TAO ZHI-FU , WANG GARY T , WANG LE , WANG XILU , WENDT MICHAEL , MANTEI ROBERT , HANSEN TODD M
IPC分类号： C07D471/04 , A61K31/437 , A61K35/00
摘要： Compuestos que inhiben la actividad de las proteínas anti-apoptóticas Bcl-2, composiciones que contienen dichos compuestos y métodos para tratar enfermedades durante las cuales se expresa la proteína anti-apoptótica Bcl-2.

107. 发明专利

CO6592044A2 Derivados de sulfonamida como agentes inductores de apoptosis con selectividad por bcl-2 para el tratamiento de cancer y enfermedadese inmunes 未知
公开(公告)号：CO6592044A2
公开(公告)日：2013-01-02
申请号：CO12111688
申请日：2012-07-04
申请人： ABBVIE INC
发明人： BRUNCKO MILAN , DING HONG , DOHERTY GEORGE , ELMORE STEVEN W , HASVOLD LISA A , HEXAMER LAURA , KUNZER AARON R , MANTEI ROBERT A , MCCLELLAN WILLIAM J , PARK CHEOL-MIN , PETROS ANDREW M , SONG XIAOHONG , SOUERS ANDREW J , SULLIVAN GERARD M , TAO ZHI-FU , WANG GARY T , WANG XILU , WANG LE , WENDT MICHAEL D , HANSEN TODD M , PARK CHANG H
IPC分类号： C07D405/12 , A61K31/404 , A61P35/00 , C07D209/32 , C07D211/96 , C07D215/20 , C07D217/16 , C07D231/56 , C07D235/26 , C07D249/04 , C07D295/125 , C07D295/14 , C07D295/195 , C07D309/14 , C07D401/12 , C07D405/14
摘要： Compuestos que inhiben la actividad de las proteínas anti-apoptóticas Bcl-2 o Bcl-XL, composiciones que contienen dichos compuestos y métodos para tratar enfermedades durante las cuales se expresa la proteína anti-apoptótica BcI-2.

108. 发明专利

CL2012001422A1 Compuestos derivados de sulfonil benzamidas sustituidas, inductores de apoptosis con selectividad por bcl-2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer. 未知
公开(公告)号：CL2012001422A1
公开(公告)日：2012-09-14
申请号：CL2012001422
申请日：2012-05-31
申请人： ABBVIE INC
发明人： BRUNCKO MILAN , DING HONG , DOHERTY GEORGE A , ELMORE STEVEN W , HASVOLD LISA , HEXAMER LAURA , KUNZER AARON , MANTEI ROBERT A , MCCLELLAN WILLIAM J , PARK CHEOL-MIN , PETROS ANDREW M , WANG GARY T , WANG LE , WANG XILU , WENDT MICHAEL D , HANSEN TODD M , PARK CHANG H , SONG XIAOHONG , SOUERS ANDREW J , SULLIVAN GERARD M , TAO ZHI-FU
IPC分类号： A61K31/416 , A61K31/4184 , A61P35/00 , C07D211/96 , C07D215/20
摘要： Compuestos derivados de sulfonil benzamidas sustituidas, inductores de apoptosis con selectividad por Bcl-2; composición farmacéutica que los comprende; y su uso para el tratamiento del cáncer.

109. 发明专利

PE20120136A1 COMPUESTOS DERIVADOS DE N-ACILSULFONAMIDAS COMO INHIBIDORES DE BCL-2 未知
公开(公告)号：PE20120136A1
公开(公告)日：2012-03-25
申请号：PE2011001147
申请日：2009-12-04
申请人： ABBVIE INC , INST MEDICAL W & E HALL
发明人： BRUNCKO MILAN , DAI YUJIA , DING HONG , DOHERTY GEORGE A , ELMORE STEVEN W , HASVOLD LISA A , HEXAMER LAURA , KUNZER AARON R , MANTEI ROBERT A , MCCLELLAN WILLIAM J , PARK CHANG H , PARK CHEOL-MIN , PETROS ANDREW M , SONG XIAOHONG , SOUERS ANDREW J , SULLIVAN GERARD M , TAO ZHI-FU , WANG GARY T , WANG LE , WANG XILU , WENDT MICHAEL D , CZABOTAR PETER EDWARD , LESSENE GUILLAUME LAURENT , COLMAN PETER MALCOM
IPC分类号： A61K31/496 , A61P35/00 , C07D403/12
摘要： SE REFIERE A COMPUESTOS HETEROCICLICOS DE FORMULA (I) DONDE A1 ES C(A2) O N, EN DONDE A2 ES H, NHC(O)NH2, SO2NH2, ENTRE OTROS; B1 ES H, C(O)NHNOH, C(NH)NH2, CN, ENTRE OTROS; D1 ES H, SO2NH2, CF3, C(O)OH, ENTRE OTROS; E1 ES H, C(NH)NH2, F, CN, ENTRE OTROS; Y1 ES H, NO2, CN, OCF3, ENTRE OTROS; Z1 ES R26 O R27, EN DONDE R26 ES FENILENO NO FUSIONADO O FUSIONADO CON BENCENO, ENTRE OTROS; R27 ES HETEROARILENO NO FUSIONADO O FUSIONADO CON BENCENO, ENTRE OTROS; Z2 ES R28, R29, ENTRE OTROS, EN DONDE R28 ES FENILENO NO FUSIONADO O FUSIONADO CON BENCENO, ENTRE OTROS; R29 ES HETEROARILENO NO FUSIONADO O FUSIONADO CON BENCENO, ENTRE OTROS; Z1A Y Z2A ESTAN AMBOS AUSENTES O FORMAN JUNTOS CH2, CH2CH2, ENTRE OTROS; L1 ES C(O)NH, SO2NH, C(N)NH, ENTRE OTROS; Z3 ES R38, R39, ENTRE OTROS, EN DONDE R38 ES FENILO NO FUSIONADO O FUSIONADO CON BENCENO, ENTRE OTROS; R39 ES HETEROARILO NO FUSIONADO O FUSIONADO CON BENCENO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 4-(4-((4'-CLORO-1,1'-BIFENIL-2-IL)METIL)PIPERAZIN-1-IL)-2-(3-((DIMETILAMINO)METIL)FENOXI)-N-((3-NITRO-4-((TETRAHIDRO-2H-PIRAN-4-ILMETIL)AMINO)FENIL)SULFONIL)BENZAMIDA; 2-(3-(ACETILAMINO)FENOXI)-4-(4-((4'-CLORO-1,1'-BIFENIL-2-IL)METIL)PIPERAZIN-1-IL)-N-((3-NITRO-4-((TETRAHIDRO-2H-PIRAN-4-ILMETIL)AMINO)FENIL)SULFONIL)BENZAMIDA; ENTRE OTROS. DICHOS COMPUESTOS INHIBEN LA ACTIVIDAD DE PROTEINAS ANTI-APOPTOTICAS Bcl-2 SIENDO UTILES EN EL TRATAMIENTO DE CANCER DE VEJIGA, LEUCEMIA LINFOBLASTICA, MELANOMA

110. 发明专利

MA52814A INHIBITEURS DE BROMODOMAINE 未知
公开(公告)号：MA52814A
公开(公告)日：2022-04-27
申请号：MA52814
申请日：2017-04-14
申请人： ABBVIE INC
发明人： FIDANZE STEVEN D , HASVOLD LISA A , LI BING , LIU DACHUN , PRATT JOHN , SCHRIMPF MICHAEL , MCDANIEL KEITH F , SHEPPARD GEORGE S , WANG LE
IPC分类号： A61K31/407 , A61K31/437 , A61P3/10 , A61P13/12 , A61P31/18 , A61P35/00 , C07D471/04 , C07D487/04

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式